



UNITED STATES
NUCLEAR REGULATORY COMMISSION
WASHINGTON, D.C. 20555-0001

July 25, 2022

Board of Pharmacy Specialties
ATTN: William M. Ellis, RPh, MS
Executive Director
2215 Constitution Avenue, NW
Washington, DC 20037-2985

SUBJECT: BOARD OF PHARMACY SPECIALTIES, COMPLETION OF THE REVIEW FOR CONTINUED RECOGNITION BY THE U.S. NUCLEAR REGULATORY COMMISSION

Dear William M. Ellis:

Thank you for responding to the U.S. Nuclear Regulatory Commission's (NRC) letter dated March 15, 2022 (Agencywide Documents Access Management System (ADAMS)¹ Accession No. ML22068A014), which requested confirmation that the Board of Pharmacy Specialties (BPS) continues to satisfy the NRC recognition criteria for specialty board certification processes in Title 10 of the *Code of Federal Regulations* (10 CFR) Part 35², "Medical Use of Byproduct Material." The NRC staff reviewed your response letter dated March 17, 2022 (ML22081A300).

The NRC staff performed a review of each NRC-recognized specialty board per the Office of Nuclear Material Safety and Safeguards (NMSS) Office Procedure MSST-70-3, "Procedures for Recognizing, Monitoring, and Terminating the Certification Process of Specialty Boards," Section 3.11, "Monitoring Continued Satisfaction of Recognition Requirements (ML20351A389)." As part of the review, the NRC staff evaluated the BPS's publicly available website at <https://www.bpsweb.org/>, as well as any provided documentation for changes that could affect the recognition of the board's certification process. Based on your response letter and the NRC's subsequent review, the NRC staff determined that the Board Certified Nuclear Pharmacist specialty area continues to satisfy the board recognition criteria in 10 CFR 35.55, "Training for an authorized nuclear pharmacist."

In addition, thank you for providing the new Board Certified Nuclear Pharmacist certificates, effective 1) January 1, 2018, to December 31, 2019, and 2) January 1, 2020, to present. The NRC staff added the certificates to the NRC public website titled "Specialty Board(s) Certification Recognized by NRC Under 10 CFR Part 35," available at <https://www.nrc.gov/materials/miau/med-use-toolkit/spec-board-cert.html>. The NRC public website is used by NRC license reviewers, as well as license reviewers in Agreement States, to verify that the certificates submitted by licensees are valid. Please ensure that BPS shares any

¹ Records are available electronically for public inspection in the NRC Public Document Room or in the NRC's ADAMS, accessible from the NRC website at <http://www.nrc.gov/reading-rm/adams.html>.

² The 10 CFR Part 35 index is available for review at: <https://www.govinfo.gov/app/collection/cfr/2021/title10/chapterI/part35>.

future changes to certificates with the NRC with the date that the revised certificates became or will become effective.

In 2019, the NRC revised its medical use regulations, including training and experience requirements. A history of the rulemaking, pertinent guidance document references, and a summary of major changes are available in a 2018 presentation titled "Final Rule – Medical Use Regulations in 10 CFR 30, 32, and 35 (ML19085A550)."³ The NRC staff have determined that BPS is in compliance, but we encourage you to review these changes if you have not done so already.

This letter further confirms that as the Executive Director of the BPS, you are the designee for all official correspondence with the NRC. If this changes in the future, please contact the NRC with the individual responsible for this role.

Please notify the NRC, via letter, if the board changes the board's name, certification processes, or certification documents because these changes could affect the recognition of certification process under the NRC requirements. In addition, please notify the NRC 6 months in advance of any plans for BPS to become inactive or disband the Board Certified Nuclear Pharmacist certification program.

For further information or for questions, please contact Maryann Ayoade at (301) 415-0862 or via email at Maryann.Ayoade@nrc.gov or Jennifer Fisher at (301) 415-1456 or via email at Jennifer.Fisher@nrc.gov.



Clark, Theresa signing on behalf
of Williams, Kevin
on 07/25/22

Kevin Williams, Director
Division of Materials Safety, Security, State,
and Tribal Programs
Office of Nuclear Material Safety
and Safeguards

³ Additional information can be found in the July 16, 2018, section of the NRC website titled "Background Information for Medical Licensees," available at <https://www.nrc.gov/materials/miau/med-use-toolkit/background-info-med-license.html#july162018>.

SUBJECT: BOARD OF PHARMACY SPECIALTIES, COMPLETION OF THE REVIEW
FOR CONTINUED RECOGNITION BY THE U.S. NUCLEAR REGULATORY
COMMISSION DATED: July 25,2022

DISTRIBUTION:

Public

T Clark, NMSS

P Longmire, NMSS

ADAMS Accession No. ML22139A327

OFFICE	NMSS/MSST	NMSS/MSST	NMSS/MSST	NMSS/MSST	NMSS/MSST
NAME	J Fisher	M Ayoade	C Valentin-Rodriguez	C Einberg	T Clark for: K Williams
DATE	07/14/2022	07/20/2022	07/21/2022	07/21/2022	07/25/2022

OFFICIAL RECORD COPY